Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression

Toxicology in Vitro

Volumn 23, Issue 8, 2009, Pages 1482-1490

  Frydrych, Ivo ^a   Mlejnek, Petr ^a   Dolezel, Petr ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Apoptosis; Differentiation; Glutathione; K562 cells; Thioredoxin reductase

Indexed keywords

BCR ABL PROTEIN; CYCLOSPORIN A; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLYCOPROTEIN P; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; THIOREDOXIN REDUCTASE; U 0123; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SENSITIZATION; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; OXIDATION REDUCTION STATE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CYCLOSPORINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FUSION PROTEINS, BCR-ABL; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMANS; IMIDAZOLES; K562 CELLS; P-GLYCOPROTEIN; PIPERAZINES; PYRIDINES; PYRIMIDINES;

EID: 70350732801     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.09.001     Document Type: Article

References (28)

1. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., and Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 22 (2003) 7468-7485
2. Armstrong J.S. Mitochondria: a target for cancer therapy. British Journal of Pharmacology 147 (2006) 239-248
3. Belhacène N., Maulon L., Guérin S., Ricci J.E., Mari B., Colin Y., Cartron J.P., and Auberger P. Differential expression of the Kell blood group and CD10 antigens: two related membrane metallopeptidases during differentiation of K562 cells by phorbol ester and hemin. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 12 (1998) 531-539
4. Borel J.F., Feurer C., Gubler H.U., and Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6 (1976) 468-475
5. De Groen P.C. Cyclosporine: a review and its specific use in liver transplantation. Mayo Clinic Proceedings 64 (1989) 680-689
6. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Bcr-Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 2 (1996) 561-566
7. Frydrych I., and Mlejnek P. Serine protease inhibitors N-alpha-tosyl-l-lysinyl-chloromethylketone (TLCK) and N-tosyl-l-phenylalaninyl-chloromethylketone (TPCK) are potent inhibitors of activated caspase proteases. Journal of Cellular Biochemistry 103 (2008) 1646-1656
8. Gotoh A., and Broxmeyer H.E. The function of BCR/ABL and related proto-oncogenes. Current Opinion in Hematology 4 (1997) 3-11
9. Gottesman M.M., and Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annual Review in Biochemistry 62 (1993) 385-427
10. Hegedus T., Orfi L., Seprodi A., Váradi A., Sarkadi B., and Kéri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochimica et Biophysica Acta 1587 (2002) 318-325
11. Heisterkamp N., Stam K., Groffen J., de Klein A., and Grosveld G. Structural organization of the bcr gene and its role in the Ph′ translocation. Nature 315 (1985) 758-761
12. Illmer T., Schaich M., Platzbecker U., Freiberg-Richter J., Oelschlägel U., von Bonin M., Porsche S., Bergemann T., Ehninger G., and Schleyer E. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18 (2004) 401-408
13. Jacquel A., Herrant M., Legros L., Belhacene N., Luciano F., Pages G., Hofman P., and Auberger P. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 17 (2003) 2160-2162
14. Javadov S., and Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cellular Physiology and Biochemistry 20 (2007) 1-22
15. Kerr J.F.R., and Harman B.V. Definition and incidence of apoptosis: an historical perspective. Apoptosis: The Molecular Basis of Cell Death (1991), Cold Spring Harbor Laboratory Press, New York 5-29
16. Kohmura K., Miyakawa Y., Kakai Y., Ikeda Y., and Kizaki M. Different roles of p38 MAPK and ERK in STI571-induced multi-lineage differentiation of K562 cells. Journal of Cellular Physiology 198 (2004) 370-376
17. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Juany D.C., Komára S., Ottmann O.G., Druker B.J., Villunger A., Roberts A.W., and Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings of the National Academy of Sciences of the United States of America 103 (2006) 14907-14912
18. Lemasters J.J., Qian T., He L., Kim J.S., Elmore S.P., Cascio W.E., and Brenner D.A. Role of mitochondrial inner membrane permeabilization in necrotic cell death, apoptosis, and autophagy. Antioxidants and Redox Signaling 4 (2002) 769-781
19. Lu J., Chew E.H., and Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proceedings of the National Academy of Sciences of the United States of America 104 (2007) 12288-12293
20. Lugo T.G., Pendergast A.M., Miller A.J., and Witte O.N. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247 (1990) 1079-1082
21. Mahon F.X., Belloc F., Lagarde V., Chollet C., Moreau-Gaudry F., Reiffers J., Goldman J.M., and Melo J.V. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 (2003) 2368-2373
22. Mlejnek P., Frydrych I., and Dolezel P. Cyclosporin A potentiates the cytotoxic effects of methyl methanesulphonate in HL-60 and K562 cells. Alternatives to Laboratory Animals: ATLA 35 (2007) 79-85
23. Noonan K.E., Beck C., Holzmayer T.A., Chin J.E., Tunder J.S., Andrulis I.L., Gazdar A.F., Willman C.L., Griffith B., Von Hoff D.D., and Roninson I.B. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proceedings of the National Academy of Sciences of the United States of America 87 (1990) 7160-7164
24. Parmar S., Katsoulidis E., Verma A., Li Y., Sassano A., Lal L., Majchrzak B., Ravandi F., Tallman M.S., Fish E.N., and Platanias L.C. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. Journal of Biological Chemistry 279 (2004) 25345-25352
25. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., and Baer M.R. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clinical Cancer Research 11 (2005) 2320-2326
26. Serkova N.J., Christians U., and Benet L.Z. Biochemical mechanisms of cyclosporine neurotoxicity. Molecular Interventions 4 (2004) 97-107
27. Shah N.P., and Sawyers C.L. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22 (2003) 7389-7395
28. Ueda S., Masutani H., Nakamura H., Tanaka T., Ueno M., and Yodoi J. Redox control of cell death. Antioxidants and Redox Signaling 4 (2002) 405-414